首页> 美国卫生研究院文献>other >Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties
【2h】

Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties

机译:再加入新型纳米二血红蛋白 - 超氧化物歧化酶 - 碳酸脱水酶 - 碳酸酐酶后降低升高的组织PCO2其是具有增强的抗氧化性能的氧气和二氧化碳载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Even though erythrocytes transport both oxygen and carbon dioxide, research on blood substitutes has concentrated on the transport of oxygen and its vasoactivity and oxidative effects. Recent study in a hemorrhagic shock animal model shows that the degree of tissue PCO2 elevation is directly related to mortality rates. We therefore prepared a novel nanobiotechnological carrier for both O2 and CO2 with enhanced antioxidant properties. This is based on the use of glutaraldehyde to crosslink stroma free hemoglobin (SFHb), superoxide dismutase (SOD), catalase (CAT) and carbonic anhydrase(CA)to form a soluble PolySFHb-SOD-CAT-CA. It was compared to blood and different resuscitation fluids on the ability to lower elevated tissue PCO2 in a 2/3 blood volume loss rat hemorrhagic shock model. Sixty minutes of sustained hemorrhagic shock at 30 mm Hg resulted in the increase of tissue PCO2 to 95 mm ± 3 mmHg from the control level of 55 mm Hg. Reinfusion of whole blood (Hb 15 g/dL with its RBC enzymes) lowered the tissue PCO2 to 72 ± 4.5 mmHg 60 minutes after reinfusion. PolySFHb-SOD-CAT-CA (SFHb 10 g/dL plus additional enzymes) was more effective than whole blood in lowering PCO2 lowering this to 66.2 ±3.5 mmHg. Ringer’s Lactated solution or polyhemoglobin lowered the elevated PCO2 only slightly to 87 ± 4.5 mmHg and 84.8 ± 1.5 mmHg, respectively. Moreover, ST-elevation for whole blood (Hb 15 g/dL) and PolySFHb-SOD-CAT-CA (Hb 10 g/dL) was respectively 12.8% ± 4% and 13.0% ± 2% of the control 60 minutes after reinfusion. Both are significantly better than those in the Ringer’s lactated group and the PolyHb group. In conclusion, this novel approach for blood substitute design has resulted in a novel nanobiotechnological carrier for both O2 and CO2 with enhanced antioxidant properties.
机译:即使红血球同时输送氧气和二氧化碳,对血液替代品的研究仍集中在氧气的输送及其血管活性和氧化作用上。失血性休克动物模型的最新研究表明,组织中PCO2升高的程度与死亡率直接相关。因此,我们为O2和CO2制备了具有增强抗氧化性能的新型纳米生物技术载体。这是基于使用戊二醛交联无基质血红蛋白(SFHb),超氧化物歧化酶(SOD),过氧化氢酶(CAT)和碳酸酐酶(CA)形成可溶性PolySFHb-SOD-CAT-CA。在降低2/3失血量大鼠失血性休克模型中,将其与血液和不同的复苏液相比,具有降低升高的组织PCO2的能力。在30毫米汞柱下持续60分钟的持续性失血性休克导致组织PCO2从55毫米汞柱的对照水平增加至95毫米±3毫米汞柱。全血(Hb 15 g / dL及其RBC酶)的再输注在输注后60分钟将组织PCO2降至72±4.5 mmHg。 PolySFHb-SOD-CAT-CA(SFHb 10 g / dL加其他酶)在降低PCO2方面降低至66.2±3.5 mmHg方面比全血更有效。林格氏乳酸溶液或多血红蛋白分别将升高的PCO2分别轻微降低至87±4.5 mmHg和84.8±1.5 mmHg。此外,再输注60分钟后,全血ST升高(Hb 15 g / dL)和PolySFHb-SOD-CAT-CA(Hb 10 g / dL)分别为对照组的12.8%±4%和13.0%±2% 。两者均明显优于林格氏乳酸组和PolyHb组。总之,这种用于血液替代品设计的新方法已经产生了一种新型的针对O2和CO2的纳米生物技术载体,具有增强的抗氧化性能。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号